In September 14th, the Korean Ministry of agriculture and Agriculture reported that safflower seeds could be used as adjuvant agents for colorectal cancer treatment. The traditional anticancer drug cis platinum platinum (cisplatin) has high anticancer activity, but the side effects of kidney injury are also large, and it is limited in clinical use. It was found that safflower seed extract can not only reduce the side effects of renal injury induced by cis platinum, but also improve its anti-cancer activity.
The animal experiment showed that the inhibition rate of colorectal cancer cell proliferation was 40% and 42% respectively when 100 and 200 grams of safflower seed extract were given alone, while the inhibition rate of colorectal cancer cells was 51%. And the use of anticancer drugs and extracts of safflower seeds when the inhibition rate is greatly improved, and the inhibitory effect is 100 grams of safflower seed extract on cancer cell proliferation rate was 67%, and 200 grams of safflower seed extract when the inhibition rate was 73%.
And the use of anticancer drugs and safflower seed extract when compared with the separate administration of anticancer drugs when the killing effect on colon cancer cells has also been improved, and with 100 grams of safflower seed extract increased by 9%, and with 200 grams of up to 20%.
The protective effect of safflower seed on renal injury induced by cancer drugs was determined by blood creatinine (creatinine) level. The blood creatinine increased by 38% when the anticancer drug was given alone, while the concentration of creatinine decreased by 11% and 16%, respectively, when compared with anticancer agents and safflower seed extract alone.
